share_log

JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target

Benzinga ·  Jun 28 22:39

JMP Securities analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:ELEV) with a Market Outperform and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment